Improper Orange Book listings harm competition, FTC says in amicus brief to antitrust suit

21 Nov 2023
endpts.com
Patent Infringement
The FTC on Monday filed an amicus brief in Mylan Pharmaceuticals’ antitrust lawsuit alleging that Sanofi abused the FDA’s Orange Book to delay and block Mylan’s generic insulin from competing with Sanofi.
In the suit, filed in May in the US District Court for the Western District of Pennsylvania, Mylan (now known as Viatris) alleges that Sanofi used the Orange Book process to block the biosimilar to insulin known as Semglee from competing with Sanofi’s branded product.
Improper Orange Book listings harm competition, FTC says in amicus brief to antitrust suit
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.